Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Tanezumab for Osteoarthritis of the Hip or Knee
DRKS00010700Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in knee osteoarthritis (OA) and hip osteoarthritis (3 arms), sponsored by Pfizer. Started Jun 2016; status: recruiting.
02
Drugs
tanezumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on DRKS00010700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010700.